News

Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment ...
Medical Dialogues10h
Roche secures USFDA Breakthrough Device Designation for AI-driven companion diagnostic for non small cell lung cancer
RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...
FMIBlog8h
Global Malignant Pleural Effusion Market Will Surge at 6% CAGR and Reach USD 8.06 Billion By 2033
The global malignant pleural effusion market will likely reach a valuation of USD 8.06 billion by 2033, rising from USD 4.5 billion in 2023. The market is slated to grow at a positive CAGR of 6% from ...
Stanford Unveils Revolutionary Blood Test That Detects Cancer and More
A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...
FDA grants breakthrough status to Roche’s VENTANA TROP2 device
The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...
F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer
RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based ...
Cancer-stricken footy WAG Kellie Finlayson hits back at 'disgusting' comparisons to notorious fraudster Belle Gibson
Online trolls had recently suggested that Kellie was lying about her diagnosis, comparing her to notorious 'cancer faker' ...
A new computational framework illuminates the hidden ecology of diseased tissues
To understand what drives disease progression in tissues, scientists need more than just a snapshot of cells in ...